news
Researchers to investigate screening for prostate cancer using MRI
A new clinical study will test for the first time if MRI scans can be used for population screening to detect prostate cancer more accurately...
List view / Grid view
Prostate cancer
news
Taking a standard prostate cancer drug with food boosts impact
By taking Zytiga with a low-fat meal could decrease the daily dose and prevent digestive issues...
news
Acoustic Cluster Therapy drives drug therapies to cancer cells
Researchers are testing the use of pulsed sound waves to direct and focus cancer drug therapies...
news
Copper PET imaging detects early recurrence of prostate cancer
An Italian study demonstrates that copper accumulation in tumours can detect prostate cancer recurrence early in patients with biochemical relapse...
news
Dietary fat, changes in fat metabolism may promote prostate cancer metastasis
Researchers have shed new light on the genetic mechanisms that promote metastasis and implicated the typical Western high-fat diet as a key environmental factor...
news
Shorter treatment course better for intermediate risk prostate cancer?
New research suggests that treatment with a shorter course of radiation using higher doses over fewer days may be the preferred approach for some men with intermediate-risk prostate cancer.
news
EC extends license for Zytiga to treat early stage prostate cancer
The EC has granted approval to broaden the existing marketing authorisation for Zytiga to include early stage metastatic prostate cancer...
news
Tapeworm drug fights prostate cancer
A Norwegian study shows that NTZ contains a substance that can kill prostate and colon cancer...
news
Q BioMed to commercialise non-narcotic metastatic cancer pain drug
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
news
Merrimack initiates Phase 1 study of MM-310 in solid tumours
29 March 2017 | By Niamh Marriott, Junior Editor
Merrimack Pharmaceuticals have enrolled its first patient in a Phase 1 study of MM-310 in solid tumours.
news
Panacea initiates Phase I prostate cancer vaccine therapy trial
19 January 2017 | By Niamh Marriott, Digital Editor
Panacea Pharmaceuticals have enrolled and dosed the first patient in the open-label, parallel designed, multi-centre Phase I clinical trial of PAN-301-1, for the treatment of persistent prostate cancer to assess safety and immunogenicity. Clinical sites for the PAN-301-1 trial are located in Alabama, California, Nebraska and South Carolina and the…
news
NICE says ‘yes’ to degarelix for men with prostate cancer and spinal metastases
1 July 2016 | By Victoria White, Digital Content Producer
NICE has recommended Ferring’s Firmagon (degarelix) for men with advanced-hormone dependent prostate cancer and spinal metastases...
news
Takeda and Roivant launch Myovant Sciences Ltd
7 June 2016 | By Victoria White, Digital Content Producer
Myovant Sciences is a biopharmaceutical company focused on delivering innovative women’s health and prostate cancer therapeutics...
news
Bayer and Orion expand BAY-1841788 programme in prostate cancer
3 June 2016 | By Victoria White, Digital Content Producer
The Phase III study ARASENS will evaluate BAY-1841788 in men with newly diagnosed metastatic hormone-sensitive prostate cancer...
news
NICE recommends Jevtana for advanced prostate cancer
25 May 2016 | By Victoria White, Digital Content Producer
Jevtana has been recommended in combination with other drugs as a treatment option for metastatic hormone-relapsed prostate cancer in England...
